drugset / Trial / NCT01232946

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946

RandomizedParallel-groupOpen-labelOther

Summary

27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).

Timeline

Start
2012-01
Primary completion
2017-09-08
Completion
2017-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous
Subject insulin detemir Protein / enzyme biologic 5 iu Subcutaneous